Considering the timeframe , I still think they off
Post# of 157648
(Total Views: 481)
Posted On: 05/07/2025 5:02:31 PM
Considering the timeframe , I still think they offered to buy our platform drug—just not enough.
Think they offered 5-10 billion (opinion)
June 29th CYDY hit $10 share. (4-5 billion mrkt cap)
STOCK IS QUICKLY AND HEAVILY SHORTED
July NP states on a webcast specificly: “to Gilead and whoever else.” Cytodyn is not worth 10-20-30 billion. It’s triple digits.
At that time we Fast track HIV…failed BLA submission, Giled knew it worked though
Covid. Patients getting off ECMO
EIND’s … Warp Speed. Gilead had Remdesivir.
Cancer Basket trial already with some partial data.(possibly see by G through Amarex )
Aug -Sept. fast and furious negotiations to buy IMMU.
Favorable trial data for Trodevly prompts Gilead to outbid themselves. Other interested party bid 55 and was not willing to pay more than 60. Gilead paid $88. A solid tumor platform to pair with CAR-T from Kite Pharma in 2017.
They decided to short us, and overpay for a less than stellar drug.
All the wrong moves will catch up to the eventually.
Think they offered 5-10 billion (opinion)
June 29th CYDY hit $10 share. (4-5 billion mrkt cap)
STOCK IS QUICKLY AND HEAVILY SHORTED
July NP states on a webcast specificly: “to Gilead and whoever else.” Cytodyn is not worth 10-20-30 billion. It’s triple digits.
At that time we Fast track HIV…failed BLA submission, Giled knew it worked though
Covid. Patients getting off ECMO
EIND’s … Warp Speed. Gilead had Remdesivir.
Cancer Basket trial already with some partial data.(possibly see by G through Amarex )
Aug -Sept. fast and furious negotiations to buy IMMU.
Favorable trial data for Trodevly prompts Gilead to outbid themselves. Other interested party bid 55 and was not willing to pay more than 60. Gilead paid $88. A solid tumor platform to pair with CAR-T from Kite Pharma in 2017.
They decided to short us, and overpay for a less than stellar drug.
All the wrong moves will catch up to the eventually.
(15)
(0)